<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980044</url>
  </required_header>
  <id_info>
    <org_study_id>09-0489</org_study_id>
    <secondary_id>R01DA027068</secondary_id>
    <nct_id>NCT00980044</nct_id>
  </id_info>
  <brief_title>Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal</brief_title>
  <official_title>Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michelle Lofwall</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prescription opioid addiction is a growing public health problem and more pharmacologic
      treatments are needed because current approved medications have had limited patient
      acceptance (naltrexone), limited availability (methadone), and concerns about misuse and
      diversion (methadone and buprenorphine). Tramadol is a currently approved medication used to
      treat moderate-severe pain, and initial studies demonstrate that it may be useful for
      treatment of the uncomfortable syndrome of opioid withdrawal without producing euphoric
      effects. This study will determine whether two different doses of extended release tramadol
      can treat opioid withdrawal and whether tramadol itself produces withdrawal after it is no
      longer taken.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Opioid Withdrawal Total Adjective Score</measure>
    <time_frame>Days 1-7</time_frame>
    <description>range of scores is 0-84; low scores indicate no opioid withdrawal, higher scores indicating more opioid withdrawal present. T</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Breakthrough Withdrawal Medication Doses Taken Week 1</measure>
    <time_frame>Days 1-7</time_frame>
    <description>There were four medications (acetaminophen for aches/pains, zolpidem for trouble sleeping, bismuth subsalicylate for diarrhea, and alumina/magnesia/simethicone for nausea/upset stomach) available to all volunteers in all treatment arms to help relieve any withdrawal symptoms that were not relieved by the blinded tramadol/placebo doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Opioid Withdrawal Adjective Total Score Week 2</measure>
    <time_frame>days 8-13</time_frame>
    <description>range of scores is 0-84; low scores indicate no opioid withdrawal, higher scores indicating more opioid withdrawal present</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Breakthrough Withdrawal Medication Doses Taken Week 2</measure>
    <time_frame>Days 8-13 (all groups now on placebo)</time_frame>
    <description>There were four medications (acetaminophen for aches/pains, zolpidem for trouble sleeping, bismuth subsalicylate for diarrhea, and alumina/magnesia/simethicone for nausea/upset stomach) available to all volunteers in all treatment arms to help relieve any withdrawal symptoms that were not relieved by the blinded tramadol/placebo doses.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Substance Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Tramadol 200 mg then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol 200 mg daily for 1 week then placebo given for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for two weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tramadol 600 mg then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tramadol 600 mg daily given for 1 week given then placebo given for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Oral Medication</description>
    <arm_group_label>Tramadol 200 mg then placebo</arm_group_label>
    <arm_group_label>Tramadol 600 mg then placebo</arm_group_label>
    <other_name>Brand name example: Ultram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Medication</description>
    <arm_group_label>Placebo for two weeks</arm_group_label>
    <other_name>Placebo is like a sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Addicted to opioids

        Exclusion Criteria:

          -  Any major medical or psychiatric disorder that would be contraindicated for
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Lofwall, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lofwall MR, Babalonis S, Nuzzo PA, Siegel A, Campbell C, Walsh SL. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend. 2013 Nov 1;133(1):188-97. doi: 10.1016/j.drugalcdep.2013.05.010. Epub 2013 Jun 4.</citation>
    <PMID>23755929</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>June 10, 2013</results_first_submitted>
  <results_first_submitted_qc>December 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2014</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Michelle Lofwall</investigator_full_name>
    <investigator_title>Principal Investigatory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Outpatient screening. Recruitment by advertisement and word or mouth.</recruitment_details>
      <pre_assignment_details>Persons screening who did not meet inclusion/ exclusion criteria were not enrolled.
Persons who did not complete the study were not included in analyses. The study was designed as an efficacy study that a priori stated it would enroll until 12 persons in each group completed the study and analyse only completers. No serious AEs in noncompleters.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tramadol 200 mg Daily</title>
          <description>Medication: Extended release tramadol 200 mg daily given for 1 week then placebo given for 1 week</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo given for two weeks</description>
        </group>
        <group group_id="P3">
          <title>Tramadol 600 mg Daily</title>
          <description>Medication: Extended release tramadol 600 mg daily given for 1 week followed by 1 week of placebo dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was a priori defined to evaluate only completers. There were 12 completers in each of the three study arms. We retained the description of the completers because it corresponds to the primary outcomes results that are reported (and this is what was proposed a priori and approved by NIDA review).</population>
      <group_list>
        <group group_id="B1">
          <title>Tramadol 200 mg</title>
          <description>Medication: Extended release tramadol for 1 week and then placebo given for 1 week</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Medication: Placebo given for two weeks</description>
        </group>
        <group group_id="B3">
          <title>Tramadol 600 mg</title>
          <description>Medication: Extended release tramadol 600 mg given for 1 week and then placebo given for 1 week</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="0.9"/>
                    <measurement group_id="B2" value="32.2" spread="2.2"/>
                    <measurement group_id="B3" value="31.6" spread="1.5"/>
                    <measurement group_id="B4" value="30.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Opioid Withdrawal Total Adjective Score</title>
        <description>range of scores is 0-84; low scores indicate no opioid withdrawal, higher scores indicating more opioid withdrawal present. T</description>
        <time_frame>Days 1-7</time_frame>
        <population>The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean across the days listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol 200 mg Daily</title>
            <description>Medication: Extended release tramadol</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Medication</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 600 mg Daily</title>
            <description>Medication: Extended release tramadol</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Opioid Withdrawal Total Adjective Score</title>
          <description>range of scores is 0-84; low scores indicate no opioid withdrawal, higher scores indicating more opioid withdrawal present. T</description>
          <population>The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean across the days listed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.1"/>
                    <measurement group_id="O2" value="7.7" spread="0.1"/>
                    <measurement group_id="O3" value="6.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Breakthrough Withdrawal Medication Doses Taken Week 1</title>
        <description>There were four medications (acetaminophen for aches/pains, zolpidem for trouble sleeping, bismuth subsalicylate for diarrhea, and alumina/magnesia/simethicone for nausea/upset stomach) available to all volunteers in all treatment arms to help relieve any withdrawal symptoms that were not relieved by the blinded tramadol/placebo doses.</description>
        <time_frame>Days 1-7</time_frame>
        <population>These are data from week 1 -- the 12 people who completed this week in each group. This is the analysis that was specified at the start of the study. The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean across the days listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol 200 mg Then Placebo</title>
            <description>Tramadol 200 mg daily for 1 week then placebo given for 1 week
Tramadol: Oral Medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Two Weeks</title>
            <description>Medication
Placebo: Oral Medication</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 600 mg Then Placebo</title>
            <description>Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
Tramadol: Oral Medication</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Breakthrough Withdrawal Medication Doses Taken Week 1</title>
          <description>There were four medications (acetaminophen for aches/pains, zolpidem for trouble sleeping, bismuth subsalicylate for diarrhea, and alumina/magnesia/simethicone for nausea/upset stomach) available to all volunteers in all treatment arms to help relieve any withdrawal symptoms that were not relieved by the blinded tramadol/placebo doses.</description>
          <population>These are data from week 1 -- the 12 people who completed this week in each group. This is the analysis that was specified at the start of the study. The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean across the days listed.</population>
          <units>Mean doses per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.2"/>
                    <measurement group_id="O2" value="2.5" spread="0.2"/>
                    <measurement group_id="O3" value="3.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Opioid Withdrawal Adjective Total Score Week 2</title>
        <description>range of scores is 0-84; low scores indicate no opioid withdrawal, higher scores indicating more opioid withdrawal present</description>
        <time_frame>days 8-13</time_frame>
        <population>The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean total withdrawal score across the days listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol 200 mg Then Placebo</title>
            <description>Tramadol 200 mg daily for 1 week then placebo given for 1 week
Tramadol: Oral Medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Two Weeks</title>
            <description>Medication
Placebo: Oral Medication</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 600 mg Then Placebo</title>
            <description>Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
Tramadol: Oral Medication</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Opioid Withdrawal Adjective Total Score Week 2</title>
          <description>range of scores is 0-84; low scores indicate no opioid withdrawal, higher scores indicating more opioid withdrawal present</description>
          <population>The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean total withdrawal score across the days listed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.2"/>
                    <measurement group_id="O2" value="2.9" spread="0.2"/>
                    <measurement group_id="O3" value="2.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Breakthrough Withdrawal Medication Doses Taken Week 2</title>
        <description>There were four medications (acetaminophen for aches/pains, zolpidem for trouble sleeping, bismuth subsalicylate for diarrhea, and alumina/magnesia/simethicone for nausea/upset stomach) available to all volunteers in all treatment arms to help relieve any withdrawal symptoms that were not relieved by the blinded tramadol/placebo doses.</description>
        <time_frame>Days 8-13 (all groups now on placebo)</time_frame>
        <population>The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean number of doses/day across the days listed.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol 200 mg Then Placebo</title>
            <description>Tramadol 200 mg daily for 1 week then placebo given for 1 week
Tramadol: Oral Medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo for Two Weeks</title>
            <description>Medication
Placebo: Oral Medication</description>
          </group>
          <group group_id="O3">
            <title>Tramadol 600 mg Then Placebo</title>
            <description>Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
Tramadol: Oral Medication</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Breakthrough Withdrawal Medication Doses Taken Week 2</title>
          <description>There were four medications (acetaminophen for aches/pains, zolpidem for trouble sleeping, bismuth subsalicylate for diarrhea, and alumina/magnesia/simethicone for nausea/upset stomach) available to all volunteers in all treatment arms to help relieve any withdrawal symptoms that were not relieved by the blinded tramadol/placebo doses.</description>
          <population>The primary analysis was ANOVA with day and treatment arm as factors. The outcome measure described below is the mean number of doses/day across the days listed.</population>
          <units>mean # of doses per day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.2"/>
                    <measurement group_id="O2" value="1.6" spread="0.1"/>
                    <measurement group_id="O3" value="3.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>There were no serious adverse events for anyone enrolled (completers and non-completers). The remaining adverse events are reported from both completers and non-completers.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tramadol 200 mg</title>
          <description>Medication: Extended release tramadol 200 mg daily for one week followed by placebo for one week</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Medication: Placebo for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>Tramadol 600 mg</title>
          <description>Medication: Extended release tramadol 600 mg daily for one week followed by placebo for one week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>Occurred in a completer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sore throat/strep B</sub_title>
                <description>Occurred in a completer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>sore throat with cough</sub_title>
                <description>Occurred in a non-completer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>athletes foot</sub_title>
                <description>Occurred in a non-completer.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>fleeting chest pain</sub_title>
                <description>Occurred in a completer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>left shoulder pain</sub_title>
                <description>Pre-existing condition -- pain due to old MVA whereby shoulder was hurt. Occurred in a non-completer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>tooth pain</sub_title>
                <description>Cracked right front tooth prior to admission to study - now with mild pain in that tooth. Occurred in a non-completer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>flank pain</sub_title>
                <description>right sided flank pain that started 2 days prior to randomization, mild severity, occurs when twisting body. Occurred in a non-completer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>unsteady urine flow without dysuria</sub_title>
                <description>Occurred in a completer</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was designed to analyze only completers (12 subjects per group so the description of study participant characteristics and outcomes are from these a prior defined n=36 (12 per group) completers.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michelle Lofwall, MD, Associate Professor</name_or_title>
      <organization>University of Kentucky College of Medicine</organization>
      <phone>8593239321</phone>
      <email>michelle.lofwall@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

